Glaucoma risk can be managed more effectively with the ability to use polygenic risk scores to identify individuals who can ...

PRS can personalize treatment strategies, potentially leading to better outcomes for POAG patients. Polygenic risk score was ...

The following is a summary of “Sodium-glucose cotransporter 2 inhibitors and glaucoma in patients with type 2 diabetes,” ...

Globally, glaucoma is the leading cause of blindness and vision loss, and it has a significant impact on quality of life (Fujiwara et al., 2022) Glaucoma is categorized as primary open-angle glaucoma ...

The results of the Mont Blanc trial were announced in October 2022. The second Phase 3 trial of NCX 470, Denali, is ongoing ...

A study published in the American Journal of Ophthalmology suggests that the use of SGLT2 inhibitors in diabetes is linked to ...

According to a new comprehensive report from The Insight Partners, the global Glaucoma Therapeutics Market is experiencing significant growth owing to ...

The beta blockers segment held the largest share of the market in 2023. In terms of indication, the glaucoma therapeutics market is segmented into open-angle glaucoma, angle closure glaucoma, and ...

Sight Sciences’ management is scheduled to present on Tuesday, December 3, 2024, at 12:30 pm PT / 3:30 pm ET. Interested parties may access a live and archived webcast of the fireside chat on the ...